Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
about
Update on rational targeted therapy in AMLPrognosis and management of acute myeloid leukemia in patients with Down syndromeSTAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious.Using functional genomics to overcome therapeutic resistance in hematological malignancies.Efficient induction of apoptosis by wee1 kinase inhibition in hepatocellular carcinoma cells.A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.Targeting cell cycle regulators in hematologic malignancies.Rational Combinations of Targeted Agents in AMLMAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repairSynergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo.Targeting developmental pathways in children with cancer: what price success?ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia.Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.Emerging cell cycle inhibitors for acute myeloid leukemia.Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.WEE1 is a validated target of the microRNA miR-17-92 cluster in leukemia.Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerATM and MET kinases are synthetic lethal with nongenotoxic activation of p53.New strategies in acute myeloid leukemia: redefining prognostic markers to guide therapy.SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stressSETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.New therapeutic strategies to treat human cancers expressing mutant p53 proteins.A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance.The chromatin-remodeling factor CHD4 is required for maintenance of childhood acute myeloid leukemia.A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.Analysis of Drug Resistance Using Kinome-Wide Functional Screens.Wee1 kinase inhibitor MK-1775 induces apoptosis of acute lymphoblastic leukemia cells and enhances the efficacy of doxorubicin involving downregulation of Notch pathway
P2860
Q26766152-E8401C95-F7BD-4A9F-A6EF-4C7D66AF9BC2Q27016577-650EB076-80D8-4CB9-B31E-DFBA02BD9BD6Q30577489-3C717E4E-BF2E-4C4C-AB44-082ACBBECF32Q34401328-8DEC907B-BB18-4E11-B08D-38AC8AF08B97Q35194021-29D75E95-04B6-4830-B402-D41F1BBC9ACAQ35287823-A3886E3D-AF40-4ABB-BF9D-972BF45EDBD6Q35334436-EFCEAC0F-C3F1-41AD-AE01-3187F5E01D4EQ35750491-60F765F4-D32B-4C9B-8467-8806788B4EBAQ36253975-E7F65005-8D32-415B-8F33-CDA6F9BE792AQ36413964-BA9D7878-88C6-4D88-B2AD-22F5F2D6A6ADQ36843733-C95A8A24-4A76-444B-A2D0-1DBEC7A8073CQ36905620-7059D79A-883A-4082-8A68-D9D39B8AF4EFQ37379680-C29183FE-9FA8-4C88-BD06-03A2E6FB878DQ37499287-FD659296-F09C-462A-8851-908F89F55965Q37602230-93849A16-AB48-40FD-9905-727E2E38268CQ37704849-DFDFFDAE-3170-4B85-8868-EAFAD2A7A36FQ38785380-38F722FD-33E2-4010-B4A8-254A215BE772Q38791488-0179B5BD-9D17-4EF9-A2F3-1AA0CC10A533Q38904522-CAE157CB-6A75-441A-A88D-02D888126C97Q39140763-03863447-03B3-41FC-B26F-9743FFF9AEFBQ39337933-DFC58B8F-BAC2-4A4B-BAE8-8F33EF349934Q41891342-A9B231B2-D414-44FB-BEB6-655E788D80C9Q42293531-ED6A6247-0453-4AB9-B8EB-79468ACD4398Q47669286-502AAD16-0692-4F57-8F50-19A7EB961779Q48590181-D1D80FF7-66B6-451A-A172-30493648E45BQ49962911-DFA4FF2F-5F3A-4EF6-A39B-57DCFF847ED5Q51176917-CC1430B2-C3AE-4CB1-B456-56660DF40A41Q52431146-89F3E86E-A765-4184-B638-CC11B3528D47Q52764412-7D69F650-C1D9-4B79-8792-5C73A99EFF4AQ53732008-1F6BF61B-636F-412E-8B08-D8C9CA589F6AQ58788872-45F7706F-1556-41D4-B7C6-AE644B9879A1
P2860
Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Integrated genomic analyses id ...... get in acute myeloid leukemia.
@en
Integrated genomic analyses id ...... get in acute myeloid leukemia.
@nl
type
label
Integrated genomic analyses id ...... get in acute myeloid leukemia.
@en
Integrated genomic analyses id ...... get in acute myeloid leukemia.
@nl
prefLabel
Integrated genomic analyses id ...... get in acute myeloid leukemia.
@en
Integrated genomic analyses id ...... get in acute myeloid leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Integrated genomic analyses id ...... rget in acute myeloid leukemia
@en
P2093
A van Linden
C M Gearheart
V Zaberezhnyy
P2860
P2888
P304
P356
10.1038/LEU.2011.392
P577
2012-01-13T00:00:00Z
P5875
P6179
1029572641